Fractyl Health — Third Quarter 2026 Earnings Summary

Fractyl Health reported positive six-month results from its REMAIN-1 Pivotal Cohort, demonstrating that the Revita procedure maintained approximately 80% of GLP-1-induced weight loss compared to 67% for the sham group with high statistical significance (p=0.0023). The company announced a strategic shift to focus exclusively on Revita, resulting in a 45% workforce reduction and the discontinuation of its Rejuva gene therapy program. Financially, Fractyl reported a net loss of $14.2 million for the third quarter of 2026 and expects its cash runway to extend into the second quarter of 2027. The company plans to submit a De Novo marketing application to the FDA in late 2026 and anticipates topline 12-month data in the first quarter of 2027.